A 12-year-old boy with refractory acute myeloid leukemia (AML) 2 was transferred to our hospital for compassionate treatment with gemtuzumab ozogamicin (GO; Mylotarg TM ). Before transfer, the patient had received 2 courses of salvage chemotherapy, after which bone marrow biopsy was negative for the disease. A plan for hematopoietic stem cell transplantation during his third cycle was halted because of disease recurrence.
CASE DESCRIPTION
A 12-year-old boy with refractory acute myeloid leukemia (AML) 2 was transferred to our hospital for compassionate treatment with gemtuzumab ozogamicin (GO; Mylotarg TM ). Before transfer, the patient had received 2 courses of salvage chemotherapy, after which bone marrow biopsy was negative for the disease. A plan for hematopoietic stem cell transplantation during his third cycle was halted because of disease recurrence.
On admission, the patient had leukemic infiltrates in his lungs, skin, distal esophagus, and gastric mucosa.
He was profoundly immunocompromised, neutropenic, anemic, and thrombocytopenic. Despite persistent fever, daily blood cultures performed at an outside hospital and on admission at our hospital were negative. The patient was treated with a comprehensive panel of antibiotics without a significant change in his persistent fever.
A day after admission, the patient began a 15-day cycle of GO therapy. On day 5, the laboratory began receiving visibly hemolyzed specimens with increased hemolysis indices. Consequently, results from multiple biochemical tests were suppressed according to laboratory protocol (Table 1 ). The laboratory was contacted to help determine whether the hemolysis was in vivo or in vitro.
